Regeneron's experimental drug aflibercept is now being tested in late-stage clinical trials, in partnership with Sanofi, in lung cancer, prostate cancer and colorectal cancer.

Regeneron Pharmaceuticals and Sanofi are conducting a Phase 3 clinical study titled A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Invest ...

Even as Sanofi and Regeneron angle to untangle their longstanding antibody-drug partnership, both drugmakers have planned to lean heavily on their split revenue from blockbuster Dupixent.

Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support ...

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Sanofi is paying Regeneron $462 million (€404 million) to exit the immuno-oncology pact it formed in 2015. The move gives Sanofi the right to opt in to two bispecific programs but otherwise ...

U.S. drugmaker Regeneron Pharmaceuticals said on Monday it would repurchase about $5 billion of its shares directly from France's Sanofi, without altering their over-a-decade-long partnership.

Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.

An experimental COPD drug from Sanofi and Regeneron showed mixed results in a pair of studies, sending the companies' shares down ...

Sanofi SNY and Regeneron REGN announced encouraging data from the confirmatory phase III LIBERTY-CUPID C study evaluating their blockbuster drug Dupixent (dupilumab) in chronicspontaneous ...

We look forward to collaborating with Sanofi and Regeneron to harness AI to accelerate advancements in disease management and improve patient access to care.” About Viz.ai, Inc.